These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3486663)

  • 1. Induction of lupus inclusions by sera from patients with systemic lupus erythematosus.
    Rich SA; Owens TR; Anzola MC; Bartholomew LE
    Arthritis Rheum; 1986 Apr; 29(4):501-7. PubMed ID: 3486663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purified recombinant human leukocyte interferons IFLrA and IFLrD induce human lupus inclusions in Raji and Daudi cells.
    Rich SA; Owens TR
    J Interferon Res; 1984; 4(3):335-45. PubMed ID: 6092490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that the interferon-induced Daudi cell human lupus inclusions are de novo synthesized complexes of ribonucleoprotein and membrane.
    Rich SA; Reilly AA
    J Biol Chem; 1989 Feb; 264(6):3529-37. PubMed ID: 2783694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon.
    Rich SA
    J Clin Invest; 1995 Jan; 95(1):219-26. PubMed ID: 7814619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus.
    von Wussow P; Jakschies D; Hochkeppel H; Horisberger M; Hartung K; Deicher H
    Arthritis Rheum; 1989 Jul; 32(7):914-8. PubMed ID: 2751723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus.
    Klippel JH; Carette S; Preble OT; Friedman RM; Grimley PM
    Ann Rheum Dis; 1985 Feb; 44(2):104-8. PubMed ID: 2983625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS.
    Vakharia DD; Szebenyi SE; Gutterman JU; Rich SA
    J Interferon Cytokine Res; 1996 Sep; 16(9):709-15. PubMed ID: 8887055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon inhibitor in the blood of patients with systemic lupus erythematosus.
    Chadha KC; Ambrus JL; Stadler I; Ambrus JL
    J Biol Regul Homeost Agents; 1991; 5(1):1-9. PubMed ID: 1715634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.
    Hooks JJ; Jordan GW; Cupps T; Moutsopoulos HM; Fauci AS; Notkins AL
    Arthritis Rheum; 1982 Apr; 25(4):396-400. PubMed ID: 6176247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of serum from patients with systemic lupus erythematosus on the immune response of normal lymphocytes.
    Jarrett MP; Grayzel AI
    J Rheumatol; 1985 Feb; 12(1):81-6. PubMed ID: 3981521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of interferon-induced lupus inclusions demonstrated by computer image reconstruction of monensin-treated Daudi cells.
    Rich SA; Marko M; Gibbons WE
    J Struct Biol; 1992; 108(1):25-34. PubMed ID: 1373290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus - an additional mechanism to increased autoantigen load?
    Bengtsson AA; Sturfelt G; Gullstrand B; Truedsson L
    Clin Exp Immunol; 2004 Mar; 135(3):535-43. PubMed ID: 15008990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human lupus inclusions and interferon.
    Rich SA
    Science; 1981 Aug; 213(4509):772-5. PubMed ID: 6166984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
    Ramaswamy M; Tummala R; Streicher K; Nogueira da Costa A; Brohawn PZ
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: roles of disease activity and serum interferon.
    Ytterberg SR; Schnitzer TJ
    Ann Rheum Dis; 1984 Jun; 43(3):457-61. PubMed ID: 6204601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum activity that confers acid lability to alpha-interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating alpha-interferon.
    Yee AM; Yip YK; Fischer HD; Buyon JP
    Arthritis Rheum; 1990 Apr; 33(4):563-8. PubMed ID: 2328034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon.
    Preble OT; Rothko K; Klippel JH; Friedman RM; Johnston MI
    J Exp Med; 1983 Jun; 157(6):2140-6. PubMed ID: 6189954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera.
    Schett G; Rubin RL; Steiner G; Hiesberger H; Muller S; Smolen J
    Arthritis Rheum; 2000 Feb; 43(2):420-8. PubMed ID: 10693884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus.
    Lood C; Tydén H; Gullstrand B; Klint C; Wenglén C; Nielsen CT; Heegaard NH; Jönsen A; Kahn R; Bengtsson AA
    PLoS One; 2015; 10(4):e0125109. PubMed ID: 25897671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera.
    Vakkalanka RK; Woo C; Kirou KA; Koshy M; Berger D; Crow MK
    Arthritis Rheum; 1999 May; 42(5):871-81. PubMed ID: 10323442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.